The Stanford Cancer Center is applying to the National Cancer Institute (NCI) for five years of funding of a Cancer Center Support Grant (CCSG) and for designation as a Comprehensive Cancer Center. Over the past three years, the Cancer Center has grown from 260 to 311 members representing four Schools within Stanford University (Medicine, Engineering, Humanities and Sciences and Law) and the Northern California Cancer Center with which Stanford has had a long-standing, scientifically productive relationship under a formal affiliation agreement. The CCSG proposal is built upon institutional strengths in technology development, particularly in the fields of imaging, biotechnology, informatics, and chemical engineering. The integration of these research areas into the fields of cancer biology, immunology, genetics and stem cell biology in the development of new approaches to cancer prevention, diagnosis and treatment is the distinguishing feature of this Cancer Center. Ten programs cover the areas of basic, translational/clinical, and population science research in cancer (Cancer Biology, Radiation Biology, Cancer Stem Cells, Cancer Imaging and Early Detection, Molecular Therapeutics, Lymphoma and Hodgkin Disease, Cancer Immunology and Immunotherapy, Hematopoietic Cell Transplantation and Immune Reconstitution, Cancer Epidemiology, and Cancer Prevention and Control). Eleven Shared Resources support the basic and translational/clinical investigation that is carried out in the Center. Based on current NCI base funding of $36 million and with $58 million in other NIH support and $16 million in other peer-reviewed cancer-relevant funding, the Center is requesting $5.3 million in direct costs to support its activities. With the advent of two new buildings for basic and translational research, new recruitment, and increased collaborative interactions, the Center is poised to make significant contributions to cancer research in the new funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA124435-06S1
Application #
8533530
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2007-06-04
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
6
Fiscal Year
2012
Total Cost
$74,997
Indirect Cost
$27,228
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Banerjee, Imon; Gensheimer, Michael Francis; Wood, Douglas J et al. (2018) Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Sci Rep 8:10037
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14

Showing the most recent 10 out of 322 publications